Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is leveraging artificial intelligence (“AI”) and machine learning (“ML”) to improve diagnostic capability using a database of biomarkers that collect data on both normal and abnormal brain information. Brain Scientific’s use of AI and ML is part of its overall strategy to penetrate the rapidly growing electroencephalogram (“EEG”) market. The strategy includes developing its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. NeuroCap is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels that can be used to record EEGs in nearly any setting. The NeuroEEG — a portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity — complements the NeuroCap. A recent article reads, “Cost-effective, portable and easily accessible, both devices together are positioned to profoundly shift the market by offering practitioners an affordable way to diagnose brain-related disorders in a range of locations, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes.”
To view the full article, visit https://ibn.fm/pWAss
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork